

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5050940

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PIETER ROTTIERS	06/16/2017
LOTHAR STEIDLER	06/16/2017
RECEIVING PARTY DATA	
Name:	INTREXON ACTOBIOTICS N.V.
Street Address:	INDUSTRIEPARK ZWIJNAARDE 7C, BUILDING D
City:	ZWIJNAARDE
State/Country:	BELGIUM
Postal Code:	B-9052
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16069947
CORRESPONDENCE DATA	
Fax Number:	(202)595-0530
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	202-842-8800
Email:	dcpatentfiling@dbi.com
Correspondent Name:	DRINKER BIDDLE & REATH (DC)
Address Line 1:	1500 K STREET, N.W.
Address Line 2:	SUITE 1100
Address Line 4:	WASHINGTON, D.C. 20005-1209
ATTORNEY DOCKET NUMBER:	205350-0030-00-US-579018
NAME OF SUBMITTER:	ZHENGYU FENG
SIGNATURE:	/Zhengyu Feng/
DATE SIGNED:	07/16/2018
Total Attachments: 3	
source=205350_0030_assignment#page1.tif	
source=205350_0030_assignment#page2.tif	
source=205350_0030_assignment#page3.tif	

DOCKET NO: INX00325WO
FILE DATE: JANUARY 13, 2017
SERIAL NO: PCT/IB2017/050204
CLAIMING PRIORITY TO
U.S. PROVISIONAL APPLICATION NOS: 62/278,493 AND 62/350,472

ASSIGNMENT

WHEREAS, WE, Pieter Rottiers of Twee Dreven 37, B-9840, De Pinte, Belgium and Lothar Steidler of Bokslaarstraat 41, B-9160, Lokeren, Belgium, have invented certain new and useful invention or inventions (hereinafter "INVENTIONS") relating to the subject matter of:

COMPOSITIONS AND METHODS FOR THE TREATMENT OF TYPE 1 DIABETES

described in International Patent Application No. PCT/IB2017/050204, filed on January 13, 2017, (hereinafter "APPLICATIONS") and claiming priority to Provisional Patent Application No. 62/278,493, filed on January 14, 2016 and Provisional Patent Application No. 62/350,472, filed on June 15, 2016, in the United States of America;

AND, WHEREAS, Intrexon Actobiotics N.V., a corporation organized and existing under and by virtue of the laws of Belgium and having an office and place of business at Technologiepark 4, B-9052 Zwijnaarde, Belgium, (hereinafter "ASSIGNEE"), is desirous of acquiring the entire right, title and interest in and to said INVENTIONS and APPLICATION, and in and to the Letters Patent to be obtained therefor under the APPLICATION;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, we do hereby assign and transfer unto said ASSIGNEE, its successors, assigns and legal representatives, our entire right, title and interest, including the right to claim priority and, including the right to sue for past infringement and to collect for all past, present and future damages in and throughout the United States of America (including its territories and dependencies) and all countries foreign thereto in and to said INVENTIONS, said APPLICATION and any inventions described therein, and any other United States applications, including priority, provisional, non-provisional, divisional, renewal, substitute, continuation, continuations-in-part, reexamination and reissue applications, based in whole or in part on said APPLICATION or in whole or in part on said INVENTIONS, any foreign applications and any inventions described therein, including priority, international, and regional applications, based in whole or in part on any of the aforesaid APPLICATION or applications or in whole or in part on said INVENTIONS, and in and to any and all Letters Patent, including extensions thereof, of any country which have been or may be granted on any of the aforesaid APPLICATION or applications or on any improvements or any parts thereof;

AND, for the consideration aforesaid, we do hereby agree that we and our executors and legal representatives will make, execute and deliver any and all other instruments in writing including any and all further application papers, affidavits, assignments, and other documents, and will communicate to said ASSIGNEE, its successors and representatives all facts known to us relating to said INVENTIONS and the history thereof and will testify in all legal proceedings and generally do all things which may be necessary or desirable more effectually to secure and to vest in said ASSIGNEE, its successors or assigns the entire right, title and interest in and to said INVENTIONS, APPLICATION, applications, and Letters Patent, rights, titles, benefits, privileges and advantages hereby sold, assigned and conveyed, or intended so to be.

AND we hereby covenant for ourselves and our legal representatives, and agree with said ASSIGNEE, its successors and assigns, that we have granted no right or license to make, use, sell or offer to sell said INVENTIONS, to anyone except said ASSIGNEE, that prior to the execution of this deed, our right, title and interest in said INVENTIONS had not been otherwise encumbered, and that we have not and will not execute any instrument in conflict therewith;

AND we do hereby authorize and request the Director of the United States Patent and Trademark Office and/or foreign equivalents to issue any and all Letters Patent which may be granted upon said APPLICATION, or upon said INVENTIONS or any parts thereof when granted, to said ASSIGNEE.

IN TESTIMONY WHEREOF, we have hereunto set my hand on the date indicated below.

DOCKET NO: INX00325WO
FILE DATE: JANUARY 13, 2017
SERIAL NO: PCT/IB2017/050204
CLAIMING PRIORITY TO

U.S. PROVISIONAL APPLICATION NOS: 62/278,493 AND 62/350,472



Pieter Rottiers




WITNESS Signature

VANDENHOVE INGE

WITNESS Print Name

16/6/2017

DATE



Lothar Steidler

WITNESS Signature

DE VRIJZE MADELINE


WITNESS Print Name

16/06/2017

DATE

DOCKET NO: INX00325WO
FILE DATE: JANUARY 13, 2017
SERIAL NO: PCT/IB2017/050204
CLAIMING PRIORITY TO
U.S. PROVISIONAL APPLICATION NOS: 62/278,493 AND 62/350,472

ACCEPTED by Intrexon Actobiotics N.V.



Signature
Name: Christian Ulrich

Title: Director

Date: June 20, 2017